Venous Thromboembolism: Review of Clinical Challenges, Biology, Assessment, Treatment, and Modeling.

Autor: Watson C; Department of Biomedical Engineering, The Pennsylvania State University, 122 Chemical and Biomedical Engineering Building, University Park, PA, 16802-4400, USA., Saaid H; Department of Biomedical Engineering, The Pennsylvania State University, 122 Chemical and Biomedical Engineering Building, University Park, PA, 16802-4400, USA., Vedula V; Department of Mechanical Engineering, Fu Foundation School of Engineering and Applied Science, Columbia University, New York, NY, USA., Cardenas JC; Department of Surgery and the Center for Translational Injury Research, McGovern Medical School, University of Texas Health Science Center, Houston, TX, USA., Henke PK; Section of Vascular Surgery, Department of Surgery, University of Michigan Health System, Ann Arbor, MI, USA., Nicoud F; CNRS, IMAG, Université de Montpellier, Montpellier, France.; Institut Universitaire de France, Paris, France., Xu XY; Department of Chemical Engineering, Imperial College London, London, UK., Hunt BJ; Department of Thrombosis and Haemostasis, King's College, London, UK.; Thrombosis and Haemophilia Centre, Guy's & St Thomas' NHS Trust, London, UK., Manning KB; Department of Biomedical Engineering, The Pennsylvania State University, 122 Chemical and Biomedical Engineering Building, University Park, PA, 16802-4400, USA. kbm10@psu.edu.; Department of Surgery, Penn State Hershey Medical Center, Hershey, PA, USA. kbm10@psu.edu.
Jazyk: angličtina
Zdroj: Annals of biomedical engineering [Ann Biomed Eng] 2024 Mar; Vol. 52 (3), pp. 467-486. Date of Electronic Publication: 2023 Nov 01.
DOI: 10.1007/s10439-023-03390-z
Abstrakt: Venous thromboembolism (VTE) is a massive clinical challenge, annually affecting millions of patients globally. VTE is a particularly consequential pathology, as incidence is correlated with extremely common risk factors, and a large cohort of patients experience recurrent VTE after initial intervention. Altered hemodynamics, hypercoagulability, and damaged vascular tissue cause deep-vein thrombosis and pulmonary embolism, the two permutations of VTE. Venous valves have been identified as likely locations for initial blood clot formation, but the exact pathway by which thrombosis occurs in this environment is not entirely clear. Several risk factors are known to increase the likelihood of VTE, particularly those that increase inflammation and coagulability, increase venous resistance, and damage the endothelial lining. While these risk factors are useful as predictive tools, VTE diagnosis prior to presentation of outward symptoms is difficult, chiefly due to challenges in successfully imaging deep-vein thrombi. Clinically, VTE can be managed by anticoagulants or mechanical intervention. Recently, direct oral anticoagulants and catheter-directed thrombolysis have emerged as leading tools in resolution of venous thrombosis. While a satisfactory VTE model has yet to be developed, recent strides have been made in advancing in silico models of venous hemodynamics, hemorheology, fluid-structure interaction, and clot growth. These models are often guided by imaging-informed boundary conditions or inspired by benchtop animal models. These gaps in knowledge are critical targets to address necessary improvements in prediction and diagnosis, clinical management, and VTE experimental and computational models.
(© 2023. The Author(s) under exclusive licence to Biomedical Engineering Society.)
Databáze: MEDLINE
Externí odkaz: